Practical use of apomorphine infusion in Parkinson's disease: lessons from the TOLEDO study and clinical experience.

Subcutaneous apomorphine infusion is a device-aided therapy for Parkinson's disease that can be considered when motor fluctuations become persistent and are no longer adequately controlled by oral/transdermal medication. Apomorphine infusion is less invasive than enteral levodopa, deep brain stimulation or focused ultrasound, and is often indicated even when neurosurgical approaches are contraindicated. This article aims to provide practical guidance for doctors and nurses initiating and treating patients with apomorphine infusion, and is based on both trial data and clinical experience from movement disorders specialists. A post hoc analysis of data from the TOLEDO randomized clinical trial of apomorphine infusion was conducted along with an analysis of 'real world' experience from 13 movement disorders specialists using a questionnaire that focused on starting patients on apomorphine infusion. Practical guidelines for starting treatment with apomorphine infusion are provided taking into consideration the regional disparities in healthcare. Apomorphine infusion is straightforward to administer but to be successful it requires concordance from the patient and family, and clinical support from an experienced team of doctors and nurses, particularly in the early months of treatment.

Introduction

Purpose Drug delivery WITHOUT BBB opening

Study Objective To provide practical, evidence- and experience-based guidance for clinicians on initiating and managing subcutaneous apomorphine infusion in Parkinson’s disease patients with persistent motor fluctuations.

Animal model / Human subject Homo sapiens (human patients with Parkinson's disease); strain: N/A; age: None; sex: None

Disease model Parkinson's disease

Cargo name and characteristics Apomorphine — a small-molecule dopamine receptor agonist (D1/D2 agonist), administered subcutaneously via continuous infusion pump as a device-aided therapy for Parkinson’s disease; titratable dosing, often requires anti-emetic cover during initiation.

Route of administration subcutaneous infusion

Outcomes and Safety

Summary of Outcomes Continuous subcutaneous apomorphine infusion reduces OFF time and improves motor fluctuations in Parkinson’s disease, is generally well tolerated with manageable adverse events (most commonly infusion-site reactions, nausea and somnolence), and typically reaches stable hourly doses around 3–7 mg/hour.

Duration of biological effect 16 hours/day

Safety-related matter Reported adverse effects include common mild-to-moderate infusion-site reactions (panniculitis, nodules, skin induration), nausea, somnolence and other dopaminergic effects (yawning, vomiting, dizziness, sedation, unwanted erections, neuropsychiatric disturbances); impulse control disorders are uncommon and orthostatic hypotension is rare and usually mild. More serious but rare safety concerns are hemolytic anemia and QTc prolongation associated with domperidone (prompting ECG and laboratory monitoring), so ongoing clinical and blood monitoring is recommended.

Brain Region

Visualization unavailable

Ultrasound Parameters

Focal Characteristics Focal depth: None; Focal length: None; Aperture size: None

Treatment frequency Multiple sessions

We are open to feedback. If you see a mistake or have a suggestion, please contact us.